

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

|  |                               |
|--|-------------------------------|
| SUBMISSION TYPE:   | NEW ASSIGNMENT                |
| NATURE OF CONVEYANCE:  | LICENSE                       |
| CONVEYING PARTY DATA   |                               |
| Name   | Execution Date                |
| InSite Vision Incorporated   | 02/15/2007                    |
| RECEIVING PARTY DATA   |                               |
| Name:  | Inspire Pharmaceuticals, Inc. |
| Street Address:  | 4222 Emperor Boulevard        |
| Internal Address:  | Suite 200                     |
| City:  | Durham                        |
| State/Country:   | NORTH CAROLINA                |
| Postal Code:   | 27703                         |
| PROPERTY NUMBERS Total: 5  |                               |
| Property Type  | Number                        |
| Patent Number:   | 6239113                       |
| Patent Number:   | 6569443                       |
| Patent Number:   | 7056893                       |
| Application Number:  | 10407425                      |
| Application Number:  | 10898170                      |
| CORRESPONDENCE DATA  |                               |
| Fax Number:  | (919)821-6800                 |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> |                               |
| Phone:   | 919-821-6614                  |
| Email:   | jtherien@smithlaw.com         |
| Correspondent Name:  | John R. Therien               |
| Address Line 1:  | 150 Fayetteville Street Mall  |
| Address Line 2:  | Suite 2500                    |
| Address Line 4:  | Raleigh, NORTH CAROLINA 27601 |
| ATTORNEY DOCKET NUMBER:  | 009047.00013.CBC              |

OP \$200.00 6239113

500231343

PATENT  
REEL: 018942 FRAME: 0539

NAME OF SUBMITTER:

John R. Therien

Total Attachments: 4

source=Exclusive Patent Notification#page1.tif

source=Exclusive Patent Notification#page2.tif

source=Exclusive Patent Notification#page3.tif

source=Exclusive Patent Notification#page4.tif

## NOTIFICATION OF EXCLUSIVE PATENT LICENSE

This NOTIFICATION OF EXCLUSIVE PATENT LICENSE is made and dated as of February 16, 2007 by and between InSite Vision Incorporated, a Delaware corporation (the "Licensor"), and Inspire Pharmaceuticals, Inc., a Delaware corporation (the "Licensee").

WHEREAS, the Licensor and the Licensee have entered into the License Agreement, dated as of February 15, 2007 (the "License Agreement") and pursuant thereto and in accordance with the terms and conditions thereof the Licensor has granted to the Licensee an exclusive license in the patents and patent applications set forth on Schedule A hereto and all issued patents and pending patent applications with priority based on such patents or patent applications or on any application on which the priority of such patents or patent applications is based, including without limitation, all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms (including regulatory extensions), and all supplementary protection certificates, together with any foreign counterparts thereof in Canada (collectively, the "Licensed Patents"), subject to the terms and conditions of such License Agreement, including with respect to certain product, field and territory limitations; and

WHEREAS, the Licensor and Licensee wish to further memorialize the exclusive license described above as it relates to the Licensed Patents;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Licensor hereby acknowledges, confirms and agrees that it has granted unto the Licensee an exclusive license in the Licensed Patents pursuant to and in accordance with the terms and conditions of the License Agreement, and Licensee hereby acknowledges, confirms, and agrees that it has accepted such grant from Licensor pursuant to and in accordance with such terms and conditions.

*[Rest of page intentionally left blank; signatures on following page]*

*[Signature page to Notification of Exclusive Patent License]*

IN WITNESS WHEREOF, the Licensor has duly executed this Notification of Exclusive Patent License as of the date first written above.

**InSite Vision Incorporated**


By: *K. Chandrasekaran*  
Name: Kumar S. Chandrasekaran, Ph.D.  
Title: CEO and Chairman

State of California )  
County of Alameda ) ss.: 530-44-2246

On this 16 day of February, 2007, before me, a Notary Public personally appeared, Kumar S. Chandrasekaran [President] of InSite Vision Incorporated, personally known to me (<sup>and</sup> or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he/~~she~~ executed the same in his/~~her~~ authorized capacity and that by his/~~her~~ signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official stamp or seal.

*Karen E. Lockman*  
Notary Public



Acknowledged and Agreed:

**Inspire Pharmaceuticals, Inc.**

By: Christy L. Shaffer  
Name: CHRISTY L. SHAFFER, Ph.D.  
Title: PRESIDENT & CEO

State of North Carolina     )  
  )  
County of Durham            )     ss.:

On this 10<sup>th</sup> day of February, 2007, before me, Laura B. Cartier personally appeared, Christy L. Shaffer, Ph.D. [President] of Inspire Pharmaceuticals, Inc., personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official stamp or seal.

Laura B. Cartier  
Notary Public

My commission expires 4/22/07

SCHEDULE A

U.S. Patent Nos.

6,239,113

6,569,443

7,056,893

U.S. Application Nos.

10/407,425

10/898,170